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MicroRNAs are key regulators of gene expression and play critical roles in both normal physiology and pathology. Recent research
has demonstrated that these molecules are present in body fluids, such as serum, plasma, and urine, and can be readily measured
using a variety of techniques. More importantly, emerging evidence suggests that circulating or urine miRNAs are useful indicators
of disease. Here, we consider the potential utility of such miRNAs as noninvasive biomarkers of prostate cancer, a disease that
would benefit substantially from novel diagnostic and prognostic tools. The studies aimed at identifying diagnostic, prognostic,
and/or predictive miRNAs for prostate cancer are summarised and reviewed. Finally, practical considerations that will influence
the translation of this recent research into clinical implementation are discussed.
1. The Clinical Problem of Prostate Cancer
Prostate cancer is the second most common solid tumour
in men worldwide and, despite significant advances in early
diagnosis and management, it remains a leading cause of
cancer-related death in men [1]. Pathological diagnosis of
prostate cancer is usually obtained by a transrectal ultra-
sound-guided biopsy prompted by elevated levels of serum
prostate-specific antigen (PSA) and/or an abnormal digital
rectal examination (DRE). The use of PSA for the diagnosis
of prostate cancer is associated with several clinical issues.
PSA is not specific for this malignancy, being elevated in
many other conditions including benign prostatic hyperpla-
sia (BPH), urinary retention, prostatitis, trauma, and physical
manipulation [2]. Moreover, elevated levels only correlate
loosely with disease severity: approximately 30% of people
with PSA 5–10 and >50% with PSA > 10 will have prostate
cancer [3]. Conversely about 10–15% of people with PSA <
5 will harbour prostate cancer [4]. Perhaps more important
than its diagnostic inaccuracy, three large clinical trials have
revealed that PSA testing/screening is associated with a high
rate of overdiagnosis and overtreatment [5–7].
Prostate cancer is characterised by distinctly unpre-
dictable outcomes from latent, slow growing tumours to
aggressive, rapidly lethal tumours. Although much effort has
been put into finding biomarkers that would improve diagno-
sis, the pertinent clinical issue is the detection of aggressive
forms of the disease at an early, curable stage. A significant
proportion of cases follow an indolent course and may not
require curative treatment. In fact, up to 40% of elderly men
will harbour cancer within their prostates at autopsy [8, 9].
However, some cancers have the potential to metastasize and
require aggressive, early clinical intervention. Unfortunately,
current clinicopathological models do not allow clinicians
to accurately discern between lethal and indolent prostate
cancer at an early stage, leading to anxiety for both clinicians
and patients about choosing the best treatment course [10].
Moreover, for the men who undergo an active surveillance
regime for low-risk prostate cancer, it remains difficult to
determine which patients will progress onto higher grade
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disease.This problem is compounded by the observation that
disease grade may be misdiagnosed in up to 47% of cases
[11].Delaying curative treatment intervention in suchpatients
could have lethal consequences.
Considering these issues, biomarkers that could improve
diagnostic accuracy and better discriminate indolent from
aggressive prostate cancers at an early stage would revolu-
tionise the clinical management of this important disease.
Moreover, identifying predictive biomarkers for the mul-
titude of new treatment strategies being developed for
metastatic prostate cancer [12] is of critical importance. In
this paper, we will present evidence for the utility of circu-
lating and urine miRNAs for such purposes.
2. MicroRNA Biogenesis and Function
MicroRNAs (miRNAs) are ∼22 nucleotide-long, single-
stranded, noncoding RNAs that were first reported in the
nematode Caenorhabditis elegans [14]. Since that seminal
finding, our understanding of miRNAs has increased sub-
stantially, and they are the best understood of the small
RNAs today. The biogenesis of miRNAs has been com-
prehensively reported in many reviews (see, e.g., [15, 16]):
briefly, long immature precursor miRNAs (pri-miRNAs)
are transcribed by RNA polymerase II and processed in
the nucleus by the RNase Drosha and nuclear protein
Pasha (DGCR8) into 70–100 bp long pre-miRNAs [17]. Pre-
miRNAs are exported to the cytoplasm by an Exportin 5-
mediated mechanism where another RNase, Dicer, generates
∼22 bp RNA duplexes [18, 19]. These dsRNAs comprise
a mature miRNA guide strand (miR-5p) and a comple-
mentary passenger strand (miR-3p or miR∗). The guide
strand is preferentially incorporated into the RNA-induced
silencing complex (RISC) and binds via partial comple-
mentarity to target sequences generally found within the
3󸀠 UTRs of target mRNAs [20, 21]. The target mRNAs are
subsequently degraded or, more commonly, repressed at a
translational level [15].
It is currently estimated that the human genome encodes
over 1800 distinct miRNAs (miRBase 19; [22]), which are
estimated to regulate ∼60% of all protein-coding genes [20].
A single miRNA can bind to multiple mRNAs and vice versa
[23], creating a complex and widespread network of miRNA:
mRNA interactions that can profoundly influence gene
expression programs. The importance of miRNAs is evi-
denced by their critical functions in essentially all normal
physiological processes, including cell cycle processes, devel-
opment, survival, differentiation, growth, apoptosis, and the
immune response [15].
3. MicroRNA Dysregulation in Cancer
Given their physiological importance, it is not surprising that
miRNAs also play important roles in the genesis and progres-
sion of cancer. This concept was first demonstrated by Calin
and colleagues, who found that a genomic region at 13q14
containing twomiRNAs (miR-15a andmiR-16-1) is frequently
deleted in leukemia [24]. Since then, the dysregulation of
miRNA expression has been demonstrated in all types of
human neoplasm. Aberrantly expressed miRNAs function in
cancer by targeting relevant coding mRNAs: oncomiRNAs
target genes that inhibitmalignancywhile tumour suppressor
miRNAs target oncogenes [25]. It is important to recognise
that these regulatory factors can have dichotomous functions
in different tumours—acting to promotemalignancy in some
and to inhibit malignancy in others—based on tumour-
specific expression patterns ofmiRNAs and their target genes.
Mechanisms by which miRNA function is altered in can-
cer include deletion/amplification of miRNA genes, modula-
tion of miRNA gene expression through epigenetic mecha-
nisms or dysregulation of transcription factors, andmutation
of miRNA loci or their target sequences [26]. Dysregulated
miRNAs can impact on many different aspects of the genesis
and progression of cancer, including proliferation, metastasis
(local invasion and colonisation), apoptosis, and angiogen-
esis, amongst others (for review, see [27]). In addition,
aberrations in miRNA processing can also modulate miRNA
function in cancer: indeed, such defects are a common
feature of malignancy. For example, Dicer was shown to be
downregulated in lung cancer and associated with reduced
postoperative survival [28]. Moreover, silencing of Dicer in
murine lung tissue enhanced the development of lung cancer
[29]. Dysregulation of genes coding for Argonaute proteins,
which are critical elements of the RISC complex, has also
been observed in a variety of malignancies including Wilms
tumours [30], colon cancer [31], and testicular cancer [32].
4. MicroRNAs as Biomarkers of Disease
The realisation that miRNAs are deregulated in human
cancers has generated considerable interest with regard to
their potential as biomarkers. miRNAs have a number of
desirable characteristics for such an application. Perhaps
most importantly,miRNA expression profiles are often tissue,
developmental, and disease specific. For example, early work
demonstrated that miRNA expression signatures accurately
distinguished between different tumour types and could
accurately identify cancers of histologically uncertain origin
[33]. Importantly, in this study the miRNA signatures were
considerably more useful than equivalent mRNA signatures.
miRNAprofiles have also been used to subtype several cancer
types, including breast and ovarian [34, 35]. Since those
seminal studies, the utility of miRNA expression profiles to
identify and stratify cancer has become increasingly evident
(for review, see [25]). Other useful attributes of miRNAs for
biomarker applications include their exceptional stability in
various types of clinical samples, including formalin-fixed
paraffin embedded tissues [36], ease of quantitation using
PCR-based assays, and conservation between species [37],
which may facilitate the use of animal models of cancer for
biomarker discovery.
Recent research has shown that miRNAs possess one
additional feature of an ideal biomarker, namely, an ability
to be sampled noninvasively. In 2008, a number of groups
reported the presence of circulating miRNAs in cell-free
fractions of blood (i.e., serum and plasma) and presented
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evidence suggesting that a subset of these molecules could
be useful indicators of disease [36, 38, 39]. Many studies
have since shown that circulating miRNAs are associated
with various malignancies and may be applied as diagnostic,
prognostic, and predictive tools (for review, see [27, 40]). Cir-
culatingmiRNAs are remarkably stable, resisting degradation
by ribonucleases and severe physicochemical conditions such
as boiling, extended storage, freeze-thawing, and extreme
pH levels [36, 41], a characteristic that will facilitate their
translation to clinical applications. This stability is due to
the presence of protective structures including proteins (e.g.,
Ago2), exosomes, microvesicles, and lipoprotein, which bind
or encapsulate cell-free miRNAs in the blood [42–45]. It
is likely that protection of circulating miRNAs facilitates
their ability to regulate gene expression in recipient cells
[46, 47]—we have previously termed such mobile miRNAs
“hormomirs” because of their potential hormone-like charac-
teristics [40]. MiRNAs have now been isolated from a range
of body fluids, greatly expanding their clinical potential [48–
50]. In a study of 12 different body fluids, the number of
detectable miRNAs ranged from 204 (urine) to 458 (saliva),
indicating that they represent a rich and diverse source of
potential biomarkers [48].
The potential of miRNAs derived from body fluids as
noninvasive biomarkers for different tumor entities has been
discussed extensively in recent review articles (see, e.g., [46,
63]). Here, we will specifically discuss the application of cir-
culating (serum and plasma) and urinemiRNAs for detection
and management of prostate cancer. Table 1 summarises the
studies that are relevant to this topic.
4.1. Circulating (Serum and Plasma) miRNAs as Biomarkers
of Prostate Cancer. The Tewari laboratory was the first to
demonstrate an association between a circulating miRNA
and prostate cancer [36]. In this pioneering study, a mouse
xenograft system was used to identify tumour-derived miR-
NAs in plasma.One of these,miR-141, was found to accurately
differentiate between men with castration-resistant prostate
cancer (CRPC) and healthy men (area under the receiver
operating characteristic curve (AUC) = 0.907).
A number of studies have assessed the potential of circu-
latingmiRNAs to diagnose early-stage, localised prostate can-
cer. Moltzahn and colleagues compared circulating miRNA
profiles in men with early-stage prostate cancer and healthy
men [52] using a novel microfluidics-based multiplex qRT-
PCR platform. Of the 10 miRNAs significantly altered in
the malignant samples, miR-106a and miR-1274 possessed
the best diagnostic capability (AUC for each = 0.928). An
approach targeting known prostate cancer-associated miR-
NAs found that miR-21 and miR-221 were elevated in the
plasma of men with localized cancer compared to healthy
controls [55]. Bryant and colleagues assessed the diagnostic
capacity of plasma miRNAs using Exiqon’s high-throughput
qRT-PCR platform [57]. Twelve miRNAs were differentially
quantitated in the circulation of men with prostate cancer (of
diverse grade and stage) compared to healthymen, withmiR-
107 showing the greatest fold change. MiR-107 had an AUC
of 0.62 compared to an AUC of 0.79 for PSA. Most recently,
profiling using an Illumina microarray platform led to the
identification of 5miRNAs—let-7c, let-7e,miR-30c,miR-622,
and miR-1285—with diagnostic capacity [59]. A signature of
the plasma levels of thesemiRNAs could differentiate prostate
cancer from BPH and healthy controls with an AUC of 0.924
and 0.860, respectively.
Other studies have focussed on identifying miRNAs
associated with metastatic disease that could be applied as
prognosticmarkers at the time of diagnosis or to detect recur-
rence following primary treatment. Our group utilized the
TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP)
model to discover circulating miRNAs that demarcated mice
with advanced disease from healthy mice [37]. Four of
the TRAMP-associated miRNAs—miR-141, miR-298, miR-
346, and miR-375—were subsequently shown to be elevated
in sera from patients with metastatic castration resistant
prostate cancer, and the intratumoural expression of miR-
375 was inversely associated with biochemical recurrence in
men treated by radical prostatectomy. This study was the
first to demonstrate that certain serum miRNAs are com-
mon between human and murine forms of prostate cancer,
highlighting the utility of mouse models for this research.
Three studies compared circulating miRNAs from men with
localised or metastatic cancer by Taqman multiplexed qRT-
PCR [53, 57, 58]. In validation cohorts, both miR-141 and
miR-375 were found to bemarkers of systemic disease in each
of the three studies. Moreover, thesemiRNAs were associated
with tumour stage and Gleason score in serum samples taken
from men with localized disease immediately prior to RP
[53]. Two other studies compared serum/plasma collected
prior to RP from men with different clinicopathological
parameters (i.e., Gleason score, tumour stage, cancer of the
prostate risk assessment (CAPRA) score, and D’Amico score)
in an effort to identify prognosticmiRNAs [52, 61]. A number
of miRNAs were associated with such clinicopathological
parameters (Table 1), but none were consistent between the
two studies.
The utility of circulating miRNAs as predictors of treat-
ment response is a particularly exciting concept. Although
the application of circulating miRNAs for this purpose is in
its infancy, two recent studies have provided evidence for
their potential in prostate cancer. Zhang and colleagues mea-
sured miR-21 levels in patients with localised and metastatic
prostate cancer and found that this miRNA was significantly
higher in CRPC patients who exhibited resistance to the
chemotherapeutic docetaxel [64]. While the sample size in
this study was small, it nevertheless represents an important
finding that warrants further investigation. A more recent
study specifically aimed to assess the utility of plasma miR-
141 as a biomarker of treatment response in patients with
metastatic prostate cancer receiving chemotherapy, hormone
therapy, or novel agents such as vaccines and kinase inhibitors
[54]. When assessing the cohort as a whole, miR-141 had a
sensitivity of 78.9% and specificity of 68.8% in predicting
clinical progression.
4.2. Urine miRNAs as Biomarkers of Prostate Cancer. For
physiological and anatomical reasons, urine may represent
a valuable source of miRNA biomarkers for urological
cancers. Bryant and colleagues were the first to test this
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Table 1: Studies investigating the potential of circulating miRNAs as biomarkers of prostate cancer.
Body fluid Sample size Methodology Key findings Reference
Plasma 25 patients (metastatic PCa), 25healthy controls
qRT-PCR
(6 miRNAs)
miR-141 levels could differentiate
metastatic PCa patients from
healthy subjects
Mitchell et al., 2008 [36]
Serum 6 patients (stages 2–4 PCa), 8healthy controls
Microarray (custom)
(547 miRNAs)
15 miRNAs were elevated in PCa
patients. However, serum miRNAs
could not distinguish between
different cancer types
Lodes et al., 2009 [51]
Serum
56 patients (20 localized PCa, 20
androgen-dependent PCa, 10
CRPC2), 6 BPH3 controls
qRT-PCR
(miR-21 only)
miR-21 was elevated in CRPC
patients compared to BPH and
associated with resistance to
docetaxel in CRPC patients
Zhang et al., 2010 [47]
Serum
29 patients (9 low risk, 11




10 miRNAs were altered in PCa
patients compared to healthy
controls. 7 miRNAs were correlated
with different risk groups
Moltzahn et al., 2011 [52]
Serum
Profiling: 7 high grade, 14 low grade




miR-141, miR-200b, and miR-375
were elevated in serum from
high-grade patients and correlated
with clinicopathological parameters
Brase et al., 2011 [53]
Plasma 21 patients (metastatic PCa) qRT-PCR(miR-141 only)
miR-141 levels were associated with
clinical progression and positively
correlated with prostate specific
antigen
Gonzales et al., 2011 [54]
Plasma
51 patients (18 localized PCa, 8 local





miR-21 and miR-221 levels were
elevated in PCa patients compared
to healthy controls. miR-21,
miR-141, and miR-221 levels were
higher in metastatic compared to
localised tumours
Agaoglu et al., 2011 [55]
Serum
45 patients (37 localized PCa, 8
metastatic), 18 BPH controls, and 20
healthy controls
qRT-PCR (5 miRNAs)
miR-26a, miR-195, and let-7i levels
were elevated in PCa compared to
BPH samples
Mahn et al., 2011 [56]
Serum
Profiling: 14 TRAMP mice, 14
healthy controls. Validation: 25







miR-141, miR-298, miR-346, and
miR-375 levels were elevated in
metastatic CRPC compared to
healthy controls. Expression of
miR-375 in primary tumours was
associated with biochemical relapse




Profiling: 78 patients (various
grades, 15 with diagnosed
metastases), 28 healthy controls.
Validation: 119 patients (47




12 circulating miRNAs were at
altered levels in PCa patients
compared to healthy controls. 16
circulating miRNAs were at altered
levels in metastatic versus localised
PCa (including miR-141 and
miR-375). Urinary levels of miR-107
and miR-574-3p exhibited
significant diagnostic value
Bryant et al., 2012 [57]
Serum
84 patients (28 low risk localised
disease, 30 high risk localised
disease, and 26 metastatic CRPC
qRT-PCR
(667 miRNAs)
miR-375, miR-141, miR-378, and
miR-409-3p were at altered levels in
metastatic CRPC compared
localised cancer
Nguyen et al., 2013 [58]
Plasma
Profiling: 25 patients (localised and
metastatic PCa), 17 BHP controls.
Validation: 80 patients (localised
and metastatic PCa), 44 BHP






5 miRNAs with significant
diagnostic value were identified
(let-7c, let-7e, miR-30c, miR-622,
and miR-1285)
Chen et al., 2012 [59]
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Table 1: Continued.
Body fluid Sample size Methodology Key findings Reference
Plasma 23 patients (15 androgen dependentPCa, 8 CRPC), 20 healthy controls
qRT-PCR
(miR-221 only)
miR-221 was elevated in PCa
patients compared to healthy
controls, and higher in
androgen-dependent PCa
compared to CRPC
Zheng et al., 2012 [60]
Plasma 82 patients (various risk scores1,5) qRT-PCR (5 miRNAs)
miR-20a, miR-21, miR-145, and
miR-221 were associated with
tumour risk scores1,5
Shen et al., 2012 [61]
Serum
72 patients (24 localised prostate
cancer, 24 bladder cancer, and 24





SNORD43may be a suitable
reference gene for the analysis of
circulating miRNA in patients with
urological malignancies
Sanders et al., 2012 [62]





concept [57]: in this study, 5 known prostate cancer-
associated miRNAs (miR-107, miR-141, miR-200b, miR-375,
and miR-574-3p) were measured in the urine of prostate
cancer patients (𝑛 = 118) and healthy controls (𝑛 = 17). The
patients underwent a digital rectal examination (DRE) before
a first pass sample enriched with prostate cells was obtained.
All of the candidate miRNAs were detectable in urine, but
only miR-107 (𝑃 = 0.001, AUC = 0.74) and miR-574-3p
(𝑃 = 0.012, AUC = 0.66) were at differential levels in men
with prostate cancer. In this cohort, the diagnostic value of
thesemiRNAswas greater than PCA3mRNA, a urinemarker
of prostate cancer [65] that has been incorporated into an
FDA-approved test (http://www.gen-probe.com/products-
services/progensa-pca3).
Collectively, the studies described above suggest that
circulating miRNAs may assist in the diagnosis, prognosis,
and prediction of prostate cancer. Unfortunately, there is little
agreement betweenmost of these studies: some of the reasons
that may underlie these conflicting results are discussed
below. One positive finding is the robust association of
miR-141 and miR-375 with metastatic disease [36, 37, 53–
55, 57, 58]. These miRNAs could potentially be applied in a
number of clinical situations: at the time of diagnosis, to iden-
tify patients with undetected micrometastases or tumours
likely to metastasise who would benefit from more aggres-
sive therapeutic strategies; following primary treatment,
to identify metastatic relapse; and to monitor treatment
response in advanced disease. In addition, it seems very likely
that these miRNAs are tumour derived [37, 66]: gaining
a better understanding of their function in normal tissues
and potential involvement in prostate cancer progression is
vital. While we believe that circulating miR-141 and miR-
375 have significant potential as novel prognostic biomarkers
of prostate cancer, it must be appreciated that both of these
molecules have been associated with other pathologies [67,
68]. Such a lack of disease specificity likely applies to other key
miRNAs in circulation. Utilising miRNA signatures rather
than measuring single miRNAs should adequately address
this issue.
4.3. Important Considerations for Quantitating Circulating
and Urine miRNAs. Many factors are likely to impact on our
ability to identify bona fide and clinically relevant miRNA
markers of disease in circulation and urine. In Figure 1, we
have integrated these factors into a concise miRNA bio-
marker discovery pipeline.
4.3.1. Sampling the Biological Material. Robust, standardised
methodology for sampling the biological material is critically
important. For example, contamination of blood fluids with
intact or lysed (i.e., haemolysis) blood cells during phle-
botomy and sample processing can have a profound effect
on the resultant miRNA profile [69–71]. Performing an addi-
tional centrifugation step after plasma/serum preparation
is likely to remove the majority of intact cellular material
[69, 70]. To estimate the extent of haemolysis, one can
measure free haemoglobin or certain miRNAs that are highly
expressed in red and white blood cells (e.g., miR-15b, miR-16,
and miR-451) [70, 71]. This may allow the removal of outlier
samples with high levels of cellular content.
Similarly, although miRNA profiling from urine is in its
infancy, it is reasonable to suggest that the sampling strategy
will have a significant impact on the measurable miRNA
milieu. Urine samples should ideally be taken as first pass
samples immediately after a DRE to enrich urine sample
for prostate cells. The commercially available urine-based
PCA3 test for prostate cancer is normally performed after a
modifiedDRE (3 strokes per lobe). A study aimed at analysing
performance characteristics of the PCA3 test found that, in
the absence of aDRE, an unacceptably lownumber of patients
(75.9% versus 96.7% following DRE) had sufficient prostate
cells in their urine for robust measurement [72]. Of note, this
study found that the PCA3 score was independent of the type
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Figure 1: Pipeline for developing circulating and urinemiRNAs as biomarkers of disease, with important considerations shown. Study design
is critical and will influence all aspects of the methodology. Clinical evaluation and translation, including clinical trials, commercialisation,
and approval, have been discussed elsewhere (e.g., see [13]) and are not included in this paper.
of DRE procedure (normal DRE versus 3 strokes per lobe
versus 8 strokes per lobe).
4.3.2. MicroRNA Extraction. Many different protocols for
isolating miRNAs from serum/plasma and urine have been
developed. In general, these protocols comprise guanidin-
ium-phenol (Trizol, Qiazol, etc.) extraction of the sample
followed by purification of miRNAs using either alcohol-
mediated precipitation or column-based methods [48, 73].
A recent study suggested that a standard liquid-liquid Tri-
zol extraction method may result in better recovery and
decreased intra-assay variance than Invitrogen mirVana
columns [70]. We have also noted increased recovery of
miRNAs using liquid-liquid phenol extraction compared to
Qiagen’s miRNeasy columns (L. A. Selth, unpublished obser-
vations), although the increased hands-on time required
for the former offset its possible benefits. In the past two
years, a number of commercial kits designed specifically for
the extraction of miRNAs from serum, plasma, urine, and
exosomes have entered the market as the volume of research
in this area has increased.Unfortunately, a robust comparison
of commercial- and laboratory-developed ad hoc purification
strategies is lacking.
4.3.3. MicroRNA Profiling. Measuring specific miRNAs or
profiling the complete miRNA population is generally
achieved using either qRT-PCR, microarrays, or next-
generation sequencing (NGS). Of these, by far the most
commonly employed is qRT-PCR, probably because of its
increased sensitivity and accuracy. Microarrays and NGS are
less sensitive but can profile many more miRNAs. Moreover,
NGS has the ability to identify previously unknown miRNAs
that would not be amplified by qRT-PCR or anneal to
microarray chips. Given that the miRNAome is likely to
expand further and the emerging notion that miRNA 5󸀠-
and 3󸀠-end structural variants, termed isomirs, are commonly
expressed and have been linked to cancer [74, 75], this
represents a significant advantage.
Each of the three aforementioned methodologies is
associated with a number of unresolved issues. Arguably,
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the most important of these is how to best normalise
miRNAmeasurements to account for biological and technical
variability. Quantitation of small RNAs extracted from 50–
400𝜇L serum/plasma using spectrophotometry is, in our
hands, not possible. Moreover, suitable reference genes in
serum/plasma/urine have not been identified: studies of
colorectal cancer and lymphoma utilised miR-16 for normal-
isation purposes [39, 76], but the utility of this miRNA for
prostate cancer has been called into question [56]. Moreover,
miR-16 is highly expressed in erythrocytes and can therefore
be heavily influenced by haemolysis [70, 71]. Sanders and
colleagues recently evaluated a series of reference small RNAs
in prostate cancer, bladder cancer, and renal cell carcinoma
and found SNORD43 to be a stable reference gene for all
threemalignancies [62].However, the suitability of SNORD43
has yet to be validated by other groups or in other prostate
cancer cohorts. To overcome these issues, a number of
guidelines have been devised. First, most protocols recom-
mend a constant starting volume of serum/plasma/urine.
Second, correcting for technical variability can be achieved
by spiking in synthetic nonhuman miRNAs (i.e., cel-miR-
39) [36, 73]. This latter guideline most commonly applies to
experiments in which selected candidate miRNAs are being
quantitated by qRT-PCR. Profiling experiments in which the
entire or large subsets of the miRNAome are measured by
qRT-PCR, microarray, or NGS afford other opportunities
for normalisation. Since data is obtained for hundreds to
thousands of miRNAs, normalisation methods that utilise
all or most of the data points, including median, quantile,
Loess, and global, can be applied [77]. These methods are
likely to correct more robustly than endogenous or spiked-
in controls. Comparisons of different normalisationmethods
for high-throughput qRT-PCR (e.g., Taqman low-density
PCR arrays) andmicroarrays have been performed (e.g., [78–
80]). The method of choice can have a significant impact
on the discovery of “differentially expressed” miRNAs and
should be carefully considered.
Two other issues in the profiling/data processing phase
must be taken into account. First, it is important to use false
discovery rate (FDR) correction when profiling large num-
bers of miRNAs with any of the methods described above.
Second, it is strongly advised that differentially expressed
miRNAs identified by microarrays or NGS are validated by
qRT-PCR, a more sensitive and accurate technique. Both of
these factors are likely to reduce false positive and other
erroneous discoveries and result in more robust disease-
associated signatures.
Finally, it is worth highlighting that urine miRNA con-
centrations can differ significantly based on the hydration
status of patients. Whilst the gold standard to account for
such differences is to measure 24-hour urine volumes, a
more feasible method may be to normalise expression data
to urinary osmolarity or specific gravity.
4.3.4. Study Design and Further Validation. Even if the exper-
imental workflow (comprising collection of the biomaterial,
extraction, miRNA profiling, and data processing) is robust,
the experiment can be impaired by a poor study design. This
factor is probably a major reason why very few markers can
be validated in further studies. A number of factors need
to be considered with the complete biomarker development
pipeline firmly in mind [13, 81]. First, cohort selection is
critical. Future studies aimed at identifying diagnostic miR-
NAs in circulation/urine should focus on clinically relevant
groups (e.g., PSA- or non-PSA screened, biopsied or not),
while studies assessing the prognostic potential of miRNAs
require cohorts with long-term clinical followup. Second,
the design and analysis strategy for these types of studies
should be determined in light of their overall objectives.Most
studies use “class discovery” or “class prediction” to identify
clinically relevant miRNA biomarkers, and these objectives
must be understood and factored into the experimental
design [82]. Finally, validation in independent sample sets
is vitally important: only a small proportion of the studies
conducted so far in prostate cancer patients have adhered to
this guideline (Table 1).
5. Concluding Remarks
While there is genuine potential for circulating and urine
miRNAs in diagnostic, prognostic, and predictive applica-
tions, clinical implementation of a noninvasive miRNA test
for prostate cancer is still a distant goal. The studies that
have been conducted thus far are heterogeneous in terms
of objectives and methodology, which have often yielded
conflicting data and outcomes. Improving the consistency
and standardisation of these factors is of critical importance.
Moreover, cohorts with long clinical followup to validate
some of the promising findings, such as the association
between miR-141 and miR-375 and metastasis, are yet to be
analysed. Despite these challenges, and in light of the fact
that circulating miRNAs were discovered just 4 years ago, we
believe that the outlook in this field is bright.
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